Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
1601-1620 of 2,251 trials

Gastrointestinal Stromal Tumors: IDRX-42 Treatment Study

We are testing a new treatment called IDRX-42 for individuals with advanced gastrointestinal stromal tumors that cannot be surgically removed. The study aims to find a safe dosage and assess how well it works against the cancer.

Gastrointestinal Stromal Tumor (GIST)1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyOncology

Lung Cancer: BMS-986507 Treatment Study

We are testing a new treatment called BMS-986507 for adults with advanced lung cancer to see if it is safe and to find the best dose when used with other therapies.

Malignant Solid TumorSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Staphylococcus Aureus Bloodstream Infections: Dalbavancin Study

We are testing a single dose of intravenous Dalbavancin against standard antibiotics for patients with bloodstream infections. The goal is to see if Dalbavancin is as effective and to evaluate its impact on recovery and quality of life.

Catheter-Related Bloodstream Infections3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Squamous Cell Carcinoma: Cetuximab with or without Paclitaxel

We are studying the effectiveness of cetuximab alone or with paclitaxel for patients with recurrent head and neck cancer after previous treatment. The goal is to see how these options affect survival and quality of life.

Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Peripheral T-Cell Lymphoma: New Drug Evaluation

We are testing new drugs for patients with relapsed or refractory peripheral T-cell lymphomas to see if they are safe and improve treatment outcomes. This trial aims to find better options for those who have not responded to existing therapies.

Relapsed or Refractory Peripheral T-Cell Lymphomas>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Rheumatoid Arthritis: CAR-T Therapy vs. Rituximab

We are comparing a new CAR-T cell therapy with rituximab for patients with active rheumatoid arthritis that hasn't responded to other treatments. The goal is to see which therapy is safer and more effective.

Rheumatoid Arthritis1-2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesRheumatology

Avapritinib: Continued Access for Previous Study Participants

We are offering ongoing access to avapritinib for adults who benefited from it in a prior study. This trial also aims to evaluate the long-term safety of the treatment.

Systemic Mastocytosis6-12 monthsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Myotonia Treatment: Mexiletine PR vs. Mexiletine IR

We are comparing two forms of mexiletine to see which one is safer and more effective for adults with non-dystrophic myotonias. This study aims to improve treatment options for conditions like myotonia congenita and paramyotonia congenita.

Myotonic DystrophyNon-Dystrophic Myotonias6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementInternal MedicineNeurology

Multiple Myeloma: Isatuximab with Novel Agents

We are studying a new combination treatment for people with relapsed or refractory multiple myeloma. This trial aims to find effective doses and evaluate how well these combinations work compared to standard treatments.

Plasma Cell Myeloma Refractory>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Multiple Myeloma: Isatuximab with Belumosudil and Dexamethasone

We are studying a new combination of treatments for people with relapsed or refractory multiple myeloma. The goal is to find the best dose and see if this combination improves treatment outcomes.

Plasma Cell Myeloma Refractory>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyOncology

Multiple Myeloma: Isatuximab with Evorpacept and Dexamethasone

We are studying a new treatment combination for people with relapsed or refractory multiple myeloma. The goal is to find the best dose and see if it improves treatment responses compared to existing options.

Plasma Cell Myeloma Refractory>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyOncology

Blood Cancers: AZD0486 Treatment Study

We are investigating whether AZD0486, alone or with other cancer drugs, is safe and effective for adults with certain blood cancers. This includes conditions like chronic lymphocytic leukemia and large B-cell lymphoma.

Mantle Cell LymphomaLarge B-Cell LymphomaChronic Lymphocytic LeukaemiaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Prostate Cancer: Apalutamide with Surgery

We are studying if adding apalutamide to standard hormone therapy helps men with high-risk prostate cancer after surgery. The goal is to see if this combination improves cancer control compared to hormone therapy alone.

Metastatic Prostate Cancer1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Primary Plasma Cell Leukemia: ARI0002h CAR-T Cell Therapy

We are studying a new CAR-T cell treatment for patients newly diagnosed with primary plasma cell leukemia. The trial aims to evaluate its safety, effectiveness, and impact on quality of life.

Plasma Cell Leukaemia>2 yearsEfficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Acute Ischemic Stroke: Mechanical Thrombectomy Study

We are studying whether adding a mechanical procedure to standard treatment helps patients with acute ischemic stroke due to large vessel blockage. The trial also examines safety and quality of life for participants.

Malignant Ischemic Stroke>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineNeurology

Hodgkin Lymphoma: Chemotherapy Alone Study

We are exploring whether chemotherapy alone is effective for patients with early-stage Hodgkin Lymphoma who have a good prognosis. This study aims to improve treatment options and monitor for potential relapses.

Classical Hodgkin LymphomaEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Hodgkin's Lymphoma: Nivolumab and Chemotherapy Study

We are studying a new treatment approach using nivolumab followed by chemotherapy for patients with Hodgkin's lymphoma that hasn't responded to previous therapy. The goal is to see if this combination improves treatment outcomes and safety.

Refractory Hodgkin LymphomaEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHematologyOncology

Kidney Transplant: Rituximab for EBV Prevention

We are studying whether early treatment with Rituximab can help prevent EBV infections and related complications in kidney transplant recipients who are EBV negative. This research aims to improve outcomes for patients receiving organs from EBV positive donors.

Epstein-Barr Virus in Kidney Transplant Patients>2 yearsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesHematologyInfectious DiseasesNephrology

Breast Cancer: Nivolumab and Novel Immunotherapies

We are studying whether nivolumab, alone or with other treatments, can help achieve a complete response in early breast cancer patients before surgery. This trial also looks at safety and how well the treatment works.

Breast Cancer≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Breast Cancer Treatment: I-BCT-1 Study

We are exploring how genetic changes in breast tumors can help select the best treatment options for patients. This study includes patients with neoadjuvant and metastatic breast cancer to improve therapy outcomes.

Breast Cancer3-6 monthsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology